We read with great interest the article by Achiron and colleagues, entitled "Open Controlled Therapeutic Trial of Intravenous Immune Globulin in Relapsing-Remitting Multiple Sclerosis."1 Unfortunately, the open trial published 10 years ago by our group2 was not cited by the authors. Our experience concerned 31 patients with multiple sclerosis, with a mean duration of treatment of about 4 years. After treatment, health conditions improved significantly (P<.01) in 11 patients, no change was observed in nine patients, and deterioration continued in 11 patients. The disease progression (ratio of disability to duration of the disease in years) declined significantly in 20 patients, and the deterioration in group 3 was not significant, suggesting that this therapy has had no deleterious effect in the patients.
This attempt was continued and is still used. A screening for antibodies to human immunodeficiency virus type 1 was decided in 1985,3 concerning 42 patients
Schuller E. Treatment of Multiple Sclerosis With Intravenous Immunoglobulins. Arch Neurol. 1994;51(3):234. doi:10.1001/archneur.1994.00540150020006
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.